Idenix Pharmaceuticals Inc.'s layoff of about one-third of its work force could knock down the firm's burn rate by as much as half, as it retools the deal with Novartis AG for the approved hepatitis B drug Tyzeka and turns efforts toward early stage compounds for hepatitis C virus and HIV. (BioWorld Today)